We won’t stop now!
PanCAN-BMS SCIENTIFIC SESSION WITH GRANTEES
WEDNESDAY, SEPTEMBER 16, 2020
Through PanCAN’s partnership with Bristol Myers Squibb (formerly Celgene), PanCAN’s Translational Research Grants have been awarded to 16 researchers across 10 different institutions for a total of $8 million. This partnership is pushing high-priority pancreatic cancer research projects toward translational next steps, moving scientific discovery to application in patients.
We're looking forward to coming together to discuss these projects and outcomes, next steps and opportunities for further collaboration.
Bristol Myers Squibb’s support has been essential for our research community. PanCAN and our research grant recipients thank you for the instrumental role you play in advancing science and bringing new treatment options to patients!
To make the most of our time during the Joint Steering Committee Meeting on Sept. 16,
watch the 15-minute presentations at the links below in advance of the meeting.
Please come prepared with questions and topics for discussion with the group.
These presentations are shared in confidence and in good faith. Please do not share the link or any information viewed within, unless you request and receive explicit written approval from the content creator.
Activating the Immune System
Immunotherapy for Pancreatic Cancer Saposin C-based Nanovesicles
Xiaoyang Qi, PhD
2020 Grantee
University of Cincinnati
Activating Anti-Tumor Immunity by Targeting A Ubl Modification
Yuan Chen, PhD
2019 Grantee
University of California, San Diego
Pro-Inflammatory Conversion of the PDAC Microenvironment
Michael Curran, PhD
2018 Grantee
MD Anderson Cancer Center
Disrupting Critical Metabolic Pathways
Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer
Kenneth Olive, PhD
2020 Grantee
Columbia University Medical Center
Exploiting a Metabolic Vulnerability Created by Epigenetic Therapy
Susan Bates, MD
2020 Grantee
Columbia University Medical Center
Targeting Syndecan1 in Pancreatic Cancer
Wantong Yao, MD, PhD
2019 Grantee
MD Anderson Cancer Center
Pre-Clinical Development of a ULK1/2 Inhibitor for Pancreatic Cancer
Nicholas Cosford, PhD
2019 Grantee
Sanford Burnham Prebys Medical Discovery Institute
ATG4 Family Members as Therapeutic Targets for Pancreatic Cancer
Sharon Gorski, PhD
2018 Grantee
British Columbia Cancer Agency Branch (BC Cancer)
Co-PI: Robert Young, MC, FRSC
Simon Fraser University
Targeting Signaling and Repair Pathways
Validation of Targets as Biomarkers for Targeted Pancreatic Cancer Therapy
Fengzhi Li, PhD
2020 Grantee
Roswell Park Comprehensive Cancer Center
Targeting dePARylation for Pancreatic Cancer Treatment
Yilun Liu, PhD
2019 Grantee
Beckman Research Institute of the City of Hope
A Novel Super-Enhancer Associated Target in Pancreatic Cancer
Andrew Lowy, MD, FACS
2019 Grantee
University of California, San Diego
Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer
Darren Carpizo, MD, PhD
2018 Grantee
University of Rochester Medical Center
Co-PI: Patrick Mehlen, PhD
Research Cancer Center of Lyon (CRCL)
Keratin 17 is a Novel Actionable Target in Pancreatic Ductal ADENOCARCINOMA
Kenneth Shroyer, MD, PhD
2018 Grantee
Stony Brook University
Co-PI: Luisa Escobar-Hoyos, PhD, MSC
Yale School of Medicine
SEPTEMBER 16, 2020 | 9 a.m. – 1:30 p.m. Pacific / Noon – 4:30 p.m. Eastern
9 – 9:15 A.M.
INTRODUCTIONS/WELCOME
Julie Fleshman, JD, MBA, President and CEO, PanCAN
Lynn Matrisian, PhD, MBA, Chief Science Officer, PanCAN
Susanna Parathath, PhD, Business Development and Global Alliances, BMS
Daniel Pierce, PhD, Executive Director, BMS
Thomas Lila, PhD, Associate Director, BMS
Peter Strack, PhD, Research Alliance Group, BMS
9:15 – 9:35 A.M.
WHAT MAKES A TRANSLATIONAL PROJECT GOOD? A PHARMA PERSPECTIVE
Daniel Pierce, PhD, Executive Director, Translational Medicine, BMS
9:35 – 9:40 A.M.
BREAK
9:40 – 10:25 A.M.
ACTIVATING THE IMMUNE SYSTEM
Xiaoyang Qi, PhD, 2020 Grantee
University of Cincinnati
Immunotherapy for Pancreatic Cancer Saposin C-based Nanovesicles
Yuan Chen, PhD, 2019 Grantee
University of California, San Diego
Activating Anti-Tumor Immunity by Targeting a Ubl Modification
Michael Curran, PhD, 2018 Grantee
MD Anderson Cancer Center
Pro-Inflammatory Conversion of the PDAC Microenvironment
10:25 – 10:30 A.M.
BREAK
10:30 – 11:50 A.M.
DISRUPTING CRITICAL METABOLIC PATHWAYS
Kenneth Olive, PhD, 2020 Grantee
Columbia University Medical Center
Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer
Susan Bates, MD, 2020 Grantee
Columbia University Medical Center
Exploiting a Metabolic Vulnerability Created by Epigenetic Therapy
Wantong Yao, MD, PhD, 2019 Grantee
MD Anderson Cancer Center
Targeting Syndecan1 in Pancreatic Cancer
Break
Nicholas Cosford, PhD, 2019 Grantee
Sanford Burnham Prebys Medical Discovery Institute
Pre-Clinical Development of a ULK1/2 Inhibitor for Pancreatic Cancer
Sharon Gorski, PhD, 2018 Grantee
British Columbia Cancer Agency Branch (BC Cancer)
ATG4 Family Members as Therapeutic Targets for Pancreatic Cancer
11:50 A.M. – 12:10 P.M.
Break
12:10 – 1:30 P.M.
TARGETING SIGNALING AND REPAIR PATHWAYS
Fengzhi Li, PhD, 2020 Grantee
Roswell Park Comprehensive Cancer Center
Validation of Targets as Biomarkers for Targeted Pancreatic Cancer Therapy
Yilun Liu, PhD, 2019 Grantee
Beckman Research Institute of the City of Hope
Targeting dePARylation for Pancreatic Cancer Treatment
Andrew Lowy, MD, FACS, 2019 Grantee
University of California, San Diego
MICAL2: A Novel Super-Enhancer Associated Target in Pancreatic Cancer
Break
Darren Carpizo, MD, PhD, 2018 Grantee
University of Rochester
Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer
Kenneth Shroyer, MD, PhD, 2018 Grantee
Stony Brook University
Keratin 17 is a Novel Actionable Target in Pancreatic Ductal Adenocarcinoma
1:30 P.M.
ADJOURN
Lynn Matrisian